EN DE
Watch Curacle Co. Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Curacle Co. Ltd. (365270) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Curacle Co. Ltd. stock KRW 5,647, price KRW 8,040, that is 29.8% below the price, quality 27 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

CC Curacle Co. Ltd. logo Thin data Nov 10, 2026

Curacle Co. Ltd.

365270 · KQ
Expensive, weak quality

Our calculation puts a fair price 30% below what the stock costs today.

Low debt
Revenue last quarter 11% below a year ago.
Fair value 5,647 KRW · Overvalued
Quality 27/100
Weak Growth (revenue 3y −87.4 %/yr in KRW)
Loss-making · -92.1% net margin (TTM)
Negative free cash flow
Trails peers (2/10)
Narrow moat 28/100 · thin data
Thin data
Estimate
Watch Curacle Co. Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

49,137 KRW 3,650 KRW Fair Value 5,647 KRW Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 3,650 KRW – 49,137 KRW · fair‑value band 4,235 KRW – 7,059 KRW · the 8,040 KRW price screens above the 5,647 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Curacle Co. in your weekly email

Every Wednesday you see whether Curacle Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging.

Show moreShow less

The company's products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- ß/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases; and MT-103, a bispecific antibody combining Tie2 agonist and anti-VEGF functions for the treatment of wAMD. It also develops MT-105 for the treatment of irritable bowel diseases; MT-201, a non-bleeding anti-thrombotic antibody targeting PD-X; MT-202, a dual-mechanism therapy combining PD-X inhibition and Tie2 agonism for the treatment of acute ischemic stroke and heart failure with preserved ejection fraction; CU71, a next-generation neurovascular stabilizer for the treatment of alzheimer's disease; and CP01-R01, a first oral endothelial stabilizer"based candidate for companion animal CKD therapy.

In addition, the company develops SOLVADYS, proprietary oral small-molecule platform for the treatment of endothelial dysfunction; and EAGLES, a flagship platform of Maptics for next-generation biologics. curacle co.,ltd. was incorporated in 2016 and is headquartered in Seoul, South Korea.

Stock analysis

Curacle Co. Ltd. (365270) currently trades at 8,040 KRW, while our estimate is 5,647 KRW, 30% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 4,235 KRW (bear) to 7,059 KRW (bull), the price of 8,040 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Curacle Co. Ltd. reported revenue of 7.1M KRW in FY2025 versus 6.3B KRW in FY2021, a compound −81.6%/yr. Reported net income was −18.1B KRW in FY2025.

Key figures

Market cap 169B KRW (≈ $127M) Micro · P/S ratio 21.4 · EPS (TTM) −342.47 KRW · Net margin −92.1% · Return on equity −22.6% · Return on assets (EBIT) −19.9% (5-year average) · Operating margin 32.8% · Revenue growth (YoY) −11.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 59% below its 52-week high and 76% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −30%, 365270 screens richer than that median.

Fair Value

Bear 4,235 KRW Fair Value 5,647 KRW Bull 7,059 KRW
Price 8,040 KRW · Downside -29.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 17
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 77
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 38
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 51
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−99.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−87.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−109.4% (2021) → −232,394.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

365270 screens overvalued: fair value 30% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Curacle Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −29.8% · Below median
Profitability
Return on assets −34.0% · Below median
Net margin (12 months) −92.1% · Bottom 25%
Operating margin (12 months) 32.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −11.0% · Below median
Balance sheet
Debt / equity 0.08× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.55× · Pricier than median
P/S (12 months) 20.50× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)96 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 365270
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 365270
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 365270
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 365270
argenx SE ARGX $971.55 $908.40 −7% vs 365270
CSL Limited CSL A$201.68 A$181.40 −10% vs 365270
Moderna, Inc MRNA $250.83 $158.70 −37% vs 365270
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 365270
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 365270
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 365270

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Curacle Co. Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Curacle Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/365270

Frequently asked questions

Is Curacle Co. Ltd. (365270) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 5,647 KRW versus a price of 8,040 KRW, about 30% lower (overvalued).
What is the fair value of 365270?
Our estimate for Curacle Co. Ltd. is 5,647 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 8,040 KRW.
What is the quality score of 365270?
Curacle Co. Ltd. has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Curacle Co. Ltd. (365270)?
Our calculated price target is the estimate of 5,647 KRW (as of Nov 10, 2026). Cautious scenario 4,235 KRW, optimistic scenario 7,059 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Curacle Co. Ltd. stock forecast for 2026?
Our estimate puts fair value at 5,647 KRW, about 30% lower versus a price of 8,040 KRW (overvalued). Cautious scenario 4,235 KRW, optimistic scenario 7,059 KRW. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Curacle Co. Ltd. (365270)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Curacle Co. Ltd. it is 5,647 KRW per share (as of Nov 10, 2026), against a price of 8,040 KRW.
Is Curacle Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 365270 trades above its calculated fair value: price 8,040 KRW, fair value 5,647 KRW, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 365270?
No. The price is what the market pays today (8,040 KRW); the fair value is what the company's own numbers justify (5,647 KRW). For Curacle Co. Ltd. the two are 2,393 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Curacle Co. Ltd. worth?
The market values Curacle Co. Ltd. at about 169B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 8,040 KRW; our models calculate a fair value of 5,647 KRW per share.
What do the bullish and bearish scenarios say about 365270?
Our models span a range for Curacle Co. Ltd.: cautious scenario 4,235 KRW, base 5,647 KRW, optimistic 7,059 KRW per share (as of Nov 10, 2026, price 8,040 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Curacle Co. Ltd. (365270)?
Balance-sheet figures for Curacle Co. Ltd. (as of Nov 10, 2026): return on equity −22.6%, debt of 0.08 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is 365270 from its 52-week high?
Curacle Co. Ltd. trades at 8,040 KRW, about 59% below its 52-week high of 19,710 KRW and 76% above the low of 4,565 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 5,647 KRW is for.
Which stocks are comparable to Curacle Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Curacle Co. Ltd. stock attractive at the current price?
The data as of Nov 10, 2026: price 8,040 KRW, calculated fair value 5,647 KRW (−30%), Quality Score 27/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Curacle Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Curacle Co. Ltd. (365270)?
The closing price on Nov 10, 2026 was 8,040 KRW. Our estimate is 5,647 KRW, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Curacle Co. Ltd. right now?
The price sits above even our optimistic bull case (7,059 KRW). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Curacle Co. Ltd.

How large is the market capitalisation of Curacle Co. Ltd. (365270)?
The market capitalisation of Curacle Co. Ltd. is 169B KRW (≈ $127M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Curacle Co. Ltd. (365270)?
The price-to-sales ratio of Curacle Co. Ltd. is 21.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Curacle Co. Ltd. (365270)?
Earnings per share at Curacle Co. Ltd. are −342.47 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Curacle Co. Ltd. (365270)?
The net margin of Curacle Co. Ltd. is −92.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Curacle Co. Ltd. (365270)?
The return on equity (ROE) of Curacle Co. Ltd. is −22.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Curacle Co. Ltd. (365270)?
On an EBIT basis the return on assets of Curacle Co. Ltd. is −19.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Curacle Co. Ltd. (365270)?
The operating margin of Curacle Co. Ltd. is 32.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Curacle Co. Ltd. (365270)?
Revenue at Curacle Co. Ltd. is growing −11.0% versus a year earlier (3y avg −87.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Curacle Co. Ltd. (365270) generate?
The free cash flow of Curacle Co. Ltd. is −13.5B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Curacle Co. Ltd. (365270) carry?
The net debt of Curacle Co. Ltd. is 9.2B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Curacle Co. Ltd. in the live analysis

One click puts Curacle Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.